- Home
- IBP vs MDGL Comparison
IBP vs MDGL Comparison
Compare IBP & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBP
- MDGL
- Stock Information
- Founded
- IBP 1977
- MDGL 2011
- Country
- IBP United States
- MDGL United States
- Employees
- IBP N/A
- MDGL N/A
- Industry
- IBP Homebuilding
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- IBP Consumer Discretionary
- MDGL Health Care
- Exchange
- IBP Nasdaq
- MDGL Nasdaq
- Market Cap
- IBP 6.7B
- MDGL 7.4B
- IPO Year
- IBP 2014
- MDGL N/A
- Fundamental
- Price
- IBP $211.27
- MDGL $329.24
- Analyst Decision
- IBP Buy
- MDGL Buy
- Analyst Count
- IBP 10
- MDGL 14
- Target Price
- IBP $252.30
- MDGL $347.33
- AVG Volume (30 Days)
- IBP 343.3K
- MDGL 662.4K
- Earning Date
- IBP 11-07-2024
- MDGL 10-31-2024
- Dividend Yield
- IBP 0.66%
- MDGL N/A
- EPS Growth
- IBP 2.96
- MDGL N/A
- EPS
- IBP 9.00
- MDGL N/A
- Revenue
- IBP $2,911,800,000.00
- MDGL $76,813,000.00
- Revenue This Year
- IBP $7.39
- MDGL N/A
- Revenue Next Year
- IBP $5.73
- MDGL $193.46
- P/E Ratio
- IBP $23.64
- MDGL N/A
- Revenue Growth
- IBP 6.10
- MDGL N/A
- 52 Week Low
- IBP $144.15
- MDGL $168.25
- 52 Week High
- IBP $281.04
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- IBP 43.26
- MDGL 65.18
- Support Level
- IBP $199.29
- MDGL $272.72
- Resistance Level
- IBP $213.18
- MDGL $342.58
- Average True Range (ATR)
- IBP 8.23
- MDGL 20.03
- MACD
- IBP -0.12
- MDGL -2.08
- Stochastic Oscillator
- IBP 33.44
- MDGL 59.14
About IBP Installed Building Products Inc.
Installed Building Products Inc is an insulation installer serving the residential new construction market and are also a diversified installer of complementary building products, including waterproofing, fire-stopping and fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving, mirrors and other products throughout the United States. The company installs fiberglass insulation, spray foam insulation, and cellulose insulation. The company has three operating segments consisting of Installation, Manufacturing and Distribution operations. Majority of revenue is generated from Installation segment.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.